Skip to main content
Skip to footer

Medical Professionals
Press Releases
Suppliers

Atara Biotherapeutics

Our Company
- About Us
- Responsibility
Technology
Pipeline
- Atara Pipeline
- Tab-cel^®
- ATA3219
- ATA3431
- ATA188
Patients & Families
Investors & Media
Careers
Contact
Medical Professionals
Press Releases
Suppliers
LinkedIn
Twitter

News
Careers

Optimization and Characterization of ATA3219: A Novel and Potent Allogeneic CD19-CAR T Therapy Without Gene Editing

Home
Site Map
Terms of Use
Privacy Policy

Medical Professionals
Press Releases
Suppliers

Our Company
Technology
Pipeline
Investors and Media
Patients and Families
Careers
Contact

Our Company
About Us
Responsibility

Technology
Technology
Manufacturing
CAR T

Investors and Media
Investors and Media
News and Events
Financial Results
ATRA Stock
Analyst Coverage
SEC Filings
Governance

Pipeline
Atara Pipeline
Tab-cel^®
ATA3219
ATA3431
ATA188

Careers
Careers Home
Career Areas
Job Search

Contact

Patients and Families
Our Mission
Stories of Strength
About EBV
PTLD
Multiple Sclerosis
Clinical Studies
Expanded Access

© 2024 Atara Biotherapeutics, Inc. All rights reserved.